WordNet
- the 9th letter of the Roman alphabet (同)i
- a potent substance that acts like a hormone and is found in many bodily tissues (and especially in semen); produced in response to trauma and may affect blood pressure and metabolism and smooth muscle activity
- a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response
PrepTutorEJDIC
- 『私は』私が
- iodineの化学記号
- =sense organ / 受信装置
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 止血の概要 overview of hemostasis
- 2. 血小板生物学 platelet biology
- 3. 初期治療に抵抗性を示したレイノー現象の治療 treatment of the raynaud phenomenon resistant to initial therapy
- 4. 全身性硬化症（強皮症）における肺血管疾患：治療 pulmonary vascular disease in systemic sclerosis scleroderma treatment
- 5. 強皮症腎クリーゼを含む全身性硬化症（強皮症）における腎疾患 renal disease in systemic sclerosis scleroderma including scleroderma renal crisis
English Journal
- Raynaud's phenomenon: From molecular pathogenesis to therapy.
- Prete M1, Fatone MC1, Favoino E2, Perosa F3.Author information 1Department of Biomedical Science and Human Oncology (DIMO), Internal Medicine, University of Bari Medical School, I-70124 Bari, Italy.2Rheumatological and Autoimmune Systemic Diseases Units, University of Bari Medical School, I-70124 Bari, Italy.3Rheumatological and Autoimmune Systemic Diseases Units, University of Bari Medical School, I-70124 Bari, Italy. Electronic address: federico.perosa@uniba.it.AbstractRaynaud's phenomenon (RP) is a well defined clinical syndrome characterized by recurrent episodes of digital vasospasm triggered by exposure to physical/chemical or emotional stress. RP has been classified as primary or secondary, depending on whether it occurs as an isolated condition (pRP) or is associated to an underlying disease, mainly a connective tissue disease (CTD-RP). In both cases, it manifests with unique "triple" (pallor, cyanosis and erythema), or "double" color changes. pRP is usually a benign condition, while sRP can evolve and be complicated by acral digital ulcers and gangrene, which may require surgical treatment. The pathogenesis of RP has not yet been entirely clarified, nor is it known whether autoantibodies have a role in RP. Even so, recent advances in our understanding of the pathophysiology have highlighted novel potential therapeutic targets. The aim of this review is to discuss the etiology, epidemiology, risk factors, clinical manifestations, recently disclosed pathogenic mechanisms underlying RP and their correlation with the available therapeutic options, focusing primarily on pRP and CTD-RP.
- Autoimmunity reviews.Autoimmun Rev.2014 Jan 10. pii: S1568-9972(14)00002-0. doi: 10.1016/j.autrev.2013.12.001. [Epub ahead of print]
- Raynaud's phenomenon (RP) is a well defined clinical syndrome characterized by recurrent episodes of digital vasospasm triggered by exposure to physical/chemical or emotional stress. RP has been classified as primary or secondary, depending on whether it occurs as an isolated condition (pRP) or is a
- PMID 24418302
- Effect of Prostaglandin I2 Analogs on Macrophage Inflammatory Protein 1α in Human Monocytes Via I Prostanoid Receptor and Cyclic Adenosine Monophosphate.
- Tsai MK, Hsieh CC, Kuo HF, Yang SN, Kuo CH, Huang MY, Tsai YM, Lee MS, Hung CH.Author information From the *Division of Nephrology, Department of Internal Medicine, Kaohsiung Armed Forces General Hospital, Kaohsiung; †Department of Nursing, MeiHo University, Pingtung; ‡Division of Cardiac Surgery, Department of Surgery, §Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University; ∥Department of Pediatrics, E-DA Hospital, I-Shou University; ¶Department of Marine Biotechnology and Resources, National Sun Yat-sen University; **Graduate Institute of Medicine, College of Medicine, ††Department of Pediatrics, Kaohsiung Medical University Hospital, and Department of Pediatrics, Faculty of Pediatrics, College of Medicine, Kaohsiung Medical University; ‡‡Department of Pediatrics, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung; §§Department of Radiation Oncology, ∥∥Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University, and ¶¶Department of Pediatrics, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, Republic of China.AbstractAIMS: Inflammation plays critical roles in atherosclerosis. Chemokines are responsible for leukocyte trafficking and involve in inflammatory diseases. Macrophage inflammatory protein 1α (MIP-1α) has been implicated in atherosclerotic lesion formation. Prostaglandin I2 (PGI2) analog, used in pulmonary hypertension, has been reported to have anti-inflammatory functions. However, little is known about its role in the MIP-1α production in human monocytes.
- Journal of investigative medicine : the official publication of the American Federation for Clinical Research.J Investig Med.2014 Jan 7. [Epub ahead of print]
- AIMS: Inflammation plays critical roles in atherosclerosis. Chemokines are responsible for leukocyte trafficking and involve in inflammatory diseases. Macrophage inflammatory protein 1α (MIP-1α) has been implicated in atherosclerotic lesion formation. Prostaglandin I2 (PGI2) analog, used in pulmon
- PMID 24402297
- A vasoconstrictor role for cyclooxygenase-1-mediated prostacyclin synthesis in mouse renal arteries.
- Liu B, Zhang Y, Zhu N, Li H, Luo W, Zhou Y.Author information Cardiovascular Research Center, Shantou Univ. Medical College, 22 Xin-Ling Rd., Shantou, China 515041. zhouyingbi35@gmail.com.AbstractThis study was to determine whether prostacyclin [prostaglandin I2 (PGI2)] evokes mouse renal vasoconstriction and, if so, the underlying mechanism(s) and how its synthesis via cyclooxygenase-1 (COX-1) influences local vasomotor reaction. Experiments were performed on vessels from C57BL/6 mice and/or those with COX-1 deficiency (COX-1(-/-)). Results showed that in renal arteries PGI2 evoked contraction more potently than in carotid arteries, where COX-1 is suggested to mediate prominent endothelium-dependent contraction. A similar result was observed with the thromboxane-prostanoid (TP) receptor agonist U46619. However, in renal arteries TP receptor antagonism, which inhibited the contraction, did not result in any relaxation in response to PGI2. Moreover, we noted that the endothelial muscarinic receptor agonist ACh evoked an increase in the production of the PGI2 metabolite 6-keto-PGF1α, which was prevented by endothelial denudation or COX-1(-/-). Interestingly, COX-1(-/-) was further found to abolish a force development that was sensitive to TP receptor antagonism and result in enhanced relaxation evoked by ACh following NO synthase inhibition. Also, in renal arteries the COX substrate arachidonic acid evoked a vasoconstrictor response, which was again abolished by COX-1(-/-). Meanwhile, nonselective COX inhibition did not show any effect in vessels from COX-1(-/-) mice. Thus, in mouse renal arteries, high expression of TP receptors together with little functional involvement from the vasodilator PGI2 receptors results in a potent vasoconstrictor effect evoked by PGI2. Also, our data imply that endogenous COX-1-mediated PGI2 synthesis leads to vasoconstrictor activity and this could be an integral part of endothelium-derived mechanisms in regulating local renal vascular function.
- American journal of physiology. Renal physiology.Am J Physiol Renal Physiol.2013 Nov 1;305(9):F1315-22. doi: 10.1152/ajprenal.00332.2013. Epub 2013 Aug 28.
- This study was to determine whether prostacyclin [prostaglandin I2 (PGI2)] evokes mouse renal vasoconstriction and, if so, the underlying mechanism(s) and how its synthesis via cyclooxygenase-1 (COX-1) influences local vasomotor reaction. Experiments were performed on vessels from C57BL/6 mice and/o
- PMID 23986518
Japanese Journal
- R-(−)-α-Methylhistamine, a Histamine H3 Receptor Agonist, Induces Endothelium-Dependent Vasodilation in Rat Mesenteric Resistance Arteries
- Sun Pengyuan,Jin Xin,Koyama Toshihiro,Li Simin,Kitamura Yoshihisa,Kawasaki Hiromu
- Biological & Pharmaceutical Bulletin 33(1), 58-63, 2010
- … A novel histamine receptor subtype, histamine H3 receptor, mediates inhibition of peripheral autonomic neurotransmission. … The present study was designed to examine vascular effects of histamine H3 receptor by using a selective histamine H3 receptor agonist, R-(−)-α methylhistamine (α-methylhistamine), in rat mesenteric resistance arteries. …
- NAID 130000140192
- IP Receptor Agonist-Induced DNA Synthesis and Proliferation in Primary Cultures of Adult Rat Hepatocytes : the Involvement of Endogenous Transforming Growth Factor-α
- KIMURA Mitsutoshi,OKAMOTO Hiroshi,NATSUME Hideshi,OGIHARA Masahiko
- Journal of pharmacological sciences 109(4), 618-629, 2009-04-20
- … To elucidate the mechanism of action of prostaglandin I2 (PGI2) and carbaprostacyclin, we studied their effect on DNA synthesis and proliferation in primary cultures of adult rat hepatocytes. … These effects of PGI2 and carbaprostacyclin were abolished by treatment with a specific IP-receptor antagonist, CAY10441 (10−9 – …
- NAID 10025736150
Related Links
- Prostacyclin receptor ( or prostaglandin I2 receptor, IP1) is a receptor for prostacyclin. It is a member of the ... [edit] References. ^ a b "Entrez Gene: PTGIR prostaglandin I2 (prostacyclin) receptor (IP)". http://www.ncbi.nlm.nih.gov/sites/ entrez?
- Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness. Hashimoto K, Graham BS, Geraci MW, FitzGerald GA, Egan K, Zhou W, Goleniewska K, O'Neal JF, Morrow JD, Durbin RK, Wright PF ...
Related Pictures
★リンクテーブル★
| リンク元 | 「プロスタグランジンI2受容体」「PGI2 receptor」「prostacyclin receptor」「プロスタグランジンI2レセプター」「epoprostenol receptor」 |
| 関連記事 | 「I」「prostaglandin」「I2」「prostaglandins」 |
「プロスタグランジンI2受容体」
- 英
- prostaglandin I2 receptor、PGI2 receptor
- 関
- エポプロステノール受容体、プロスタサイクリン受容体、プロスタグランジンI2レセプター、PGI2レセプター、PGI2受容体
「PGI2 receptor」
「prostacyclin receptor」
「プロスタグランジンI2レセプター」
「epoprostenol receptor」
「I」
「prostaglandin」
[★] プロスタグランジン prostaglandins PG